Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “market outperform” rating restated by investment analysts at Citizens Jmp in a report issued on Monday,Benzinga reports. They presently have a $34.00 price objective on the stock. Citizens Jmp’s price objective points to a potential upside of 151.57% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Robert W. Baird set a $49.00 price target on Lyell Immunopharma and gave the company an “outperform” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Finally, Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Lyell Immunopharma currently has an average rating of “Moderate Buy” and an average price target of $43.00.
View Our Latest Stock Analysis on LYEL
Lyell Immunopharma Trading Up 0.1%
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting analysts’ consensus estimates of ($1.10). The business had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. On average, equities analysts predict that Lyell Immunopharma will post -7.87 EPS for the current year.
Hedge Funds Weigh In On Lyell Immunopharma
Several institutional investors and hedge funds have recently bought and sold shares of LYEL. Charles Schwab Investment Management Inc. grew its stake in shares of Lyell Immunopharma by 7.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after buying an additional 5,913 shares during the period. BBR Partners LLC purchased a new stake in shares of Lyell Immunopharma during the 4th quarter valued at approximately $210,000. ExodusPoint Capital Management LP acquired a new position in Lyell Immunopharma in the fourth quarter valued at approximately $262,000. Marshall Wace LLP acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $94,000. Finally, Two Sigma Investments LP grew its position in Lyell Immunopharma by 107.0% in the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after acquiring an additional 10,768 shares during the period. 66.05% of the stock is currently owned by institutional investors and hedge funds.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
Featured Stories
- Five stocks we like better than Lyell Immunopharma
- Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
- Mission Control: Floating In SpaceX’s Record-Breaking Orbit
- Forget AI for a Moment, This Homebuilder Is Stealing the Show
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
